On June 30, 2025, Regeneron Pharmaceuticals (NasdaqGS:REGN) was removed from multiple key indices, a development that may influence its investment appeal and stock liquidity. Over the last month ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron purchased the pioneering company for $256 million at bankruptcy auction with the intent of using its genomic data to fuel drug discovery, the company said in a Monday statement.

On June 30, 2025, Regeneron Pharmaceuticals (NasdaqGS:REGN) was removed from multiple key indices, a development that may influence its investment appeal and stock liquidity. Over the last month, the ...